http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Emergent BioSolutions (EBS) Wins $379.6M Procurement Contract to Supply RSDL to US DoD
-
Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
-
Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
-
Emergent BioSolutions (EBS) Announces FDA Accepts sNDA for OTC NARCAN
-
Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
-
Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
-
Emergent BioSolutions (EBS) Announces DoD Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
-
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
-
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
-
Emergent BioSolutions Reports Financial Results For Third Quarter 2022
-
Emergent BioSolutions Reports Financial Results For Third Quarter 2022
-
Emergent BioSolutions (EBS) Presents Data from Phase 2 Study of Chikungunya
-
Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
-
Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
-
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
-
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
-
Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
-
Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
-
Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
-
Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
-
Emergent BioSolutions (EBS) Initiates Phase 1 Study Lassa Virus Vaccine Candidate EBS-LASV
-
Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate
-
Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate
-
Emergent BioSolutions to Participate in Investor Conferences
-
Emergent BioSolutions to Participate in Investor Conferences
-
Emergent BioSolutions Reports Financial Results for Second Quarter 2022
-
Emergent BioSolutions Reports Financial Results for Second Quarter 2022
-
Emergent BioSolutions to Release Second Quarter 2022 Financial Results and Conduct Conference Call on August 1, 2022
-
Emergent BioSolutions to Release Second Quarter 2022 Financial Results and Conduct Conference Call on August 1, 2022
-
Emergent BioSolutions (EBS) and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga Treatment for Ebola
-
Emergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for Ebola
-
Emergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for Ebola
-
Emergent BioSolutions (EBS) Appoints Sujata Dayal to its Board
-
Emergent BioSolutions Announces Appointment of Sujata Dayal to Board of Directors
-
Emergent BioSolutions Announces Appointment of Sujata Dayal to Board of Directors
-
Emergent BioSolutions (EBS) Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
-
Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
-
Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
-
Emergent BioSolutions (EBS) Announces Phase 2 Safety and Immunogenicity Data of CHIKV VLP in The Lancet
-
Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases
-
Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases
-
Emergent BioSolutions to Participate in Investor Conferences
-
Emergent BioSolutions to Participate in Investor Conferences
-
Emergent BioSolutions (EBS) to Acquire Chimerix's (CMRX) Exclusive Worldwide Rights to TEMBEXA for up to $325M
-
Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
-
Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
-
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT
-
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT
-
Emergent BioSolutions Reports Financial Results For First Quarter 2022
-
Emergent BioSolutions Reports Financial Results For First Quarter 2022
